HRMY Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
268.9M
+2.9%
261.3M
+21.3%
215.4M
-11.6%
243.8M
+1.8%
239.5M
Cost of Revenue
80.7M
+27.7%
63.2M
+42.0%
44.5M
-35.1%
68.5M
+14.9%
59.6M
Gross Profit
188.2M
-5.0%
198.1M
+15.9%
170.9M
-2.5%
175.2M
-2.5%
179.8M
Operating Expenses
134.0M
+23.2%
108.8M
-18.6%
133.6M
-2.3%
136.7M
+19.6%
114.3M
R&D
71.7M
+53.8%
46.6M
-32.8%
69.4M
+39.0%
49.9M
-9.1%
55.0M
SG&A
62.4M
+0.3%
62.2M
-3.2%
64.2M
-26.0%
86.7M
+46.1%
59.4M
Operating Income
54.2M
-39.3%
89.3M
+139.5%
37.3M
-3.3%
38.6M
-41.1%
65.5M
EBITDA
72.1M
-13.5%
83.4M
+92.7%
43.3M
-5.9%
46.0M
-44.8%
83.4M
Net Income
48.2M
-36.1%
75.4M
+132.2%
32.5M
+44.5%
22.5M
-55.8%
50.9M
EPS (Basic)
$0.83
-36.2%
$1.30
+132.1%
$0.56
+43.6%
$0.39
-55.7%
$0.88
EPS (Diluted)
$0.81
-36.7%
$1.28
+132.7%
$0.55
+44.7%
$0.38
-56.3%
$0.87
Shares (Diluted)
59.7M
+1.6%
58.8M
-0.0%
58.8M
+0.5%
58.5M
-0.4%
58.7M
Harmony Biosciences (HRMY) — Financials